 patients chronic stable exertional angina periods drug trials safety standard therapy patients stable angina placebo-controlled trials events trials antianginal drugs support new drug applications US Food Drug Administration Persons trials cause due cardiovascular events causes knowledge drug assignment subjects randomized double-blind phase placebo-controlled protocols withdrew cardiovascular events difference risk adverse events drug placebo groups subgroup analysis groups calcium antagonists risk dropout placebo groups disproportionate number adverse events studies drug conclusion adverse experiences short-term placebo use active treatment risk serious cardiac events